 |
|
|
| |
The role of HIV/HBV/HCV triple infection in end stage
liver disease (ESLD) and all cause mortality in Europe
|
| |
| |
CROI 2022 Feb 11-16
A Mocroft1,2, A Geressu3, C Beguelin4, JM Llibre5, JV Lazarus6, J Tomazic7, J Smidt8, M Parczewski9, J Brännström 10, D Sedlacek11, O Degen12, M van der Valk13, 14, D Paduta15, L Flamholc16, P Schmid17, C Orkin18, LN Nielsen19, C Hoffmann20, M Beniowski21, R Radoi22, J Begovac23, L Peters1 for the EuroSIDA study*
1University of Copenhagen, Copenhagen, Denmark. 2UCL, London, UK. 3Royal Lancaster Infirmary, Lancaster, UK. 4University of Bern, Bern, Switzerland. 5Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. 6 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. 7Ljubljana University Medical Center, Ljubljana, Slovenia. 8Narva AIDS Centre, Kohtla-Järve, Estonia. 9Pomeranian Medical University, Szczecin, Poland. 10Venhälsan, Södersjukhuset, Sweden. 11Charles University Hospital Plzen, Plzem, Czech Republic. 12University Clinic Hamburg Eppendorf, Hamburg, Germany. 13Stichting HIV Monitoring, Amsterdam, The Netherlands. 14Amsterdam University Medical Centers, Amsterdam, The Netherlands. 15Gomel Regional Centre for Hygiene, Gomel, Belarus. 16Skåne University Hospital, Malmö, Sweden. 17Cantonal Hospital St. Gallen, St. Gallen, Switzerland. 18Royal London Hospital, London, UK. 19Nordsjællands Hospital, Hillerød, Denmark. 20ICH Study Center Hamburg, Hamburg, Germany. 21Diagnostics and Therapy for AIDS, Specialistic Hospital, Chorzów, Poland. 22Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania. 23University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia.
|
| |
|
|
|
|
|
